Apyx Medical (APYX)
(Delayed Data from NSDQ)
$1.19 USD
-0.04 (-3.25%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.19 USD
-0.04 (-3.25%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Zacks News
Hill-Rom (HRC) to Boost Cardiology Portfolio with New Buyout
by Zacks Equity Research
Hill-Rom's (HRC) acquisition of Bardy Diagnostics enables the former to expand into ambulatory cardiac monitoring space to accelerate digital health offering.
Apyx (APYX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apyx (APYX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx (APYX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 18.75% and 3.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 17.65% and 71.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Surges: Stock Moves 10.3% Higher
by Zacks Equity Research
NanoString Technologies (NSTG) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.
Why Apyx (APYX) Stock Might be a Great Pick
by Zacks Equity Research
Apyx (APYX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Canopy Growth (CGC) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Canopy Growth (CGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Will Apyx Medical Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Apyx Medical
Quidel (QDEL) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Quidel (QDEL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
PetIQ (PETQ) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
PetIQ (PETQ) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Apyx Medical (APYX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 72.73% and -5.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Apyx (APYX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for November 21st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 21st
Will Apyx Medical Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Apyx Medical.
Apyx (APYX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 27.78% and 13.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Apyx Medical (APYX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Apyx (APYX) a New Buy Stock
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 27.78% and 7.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Apyx Medical (APYX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.